SAGE Therapeutics Inc. (NASDAQ:SAGE) Hits New Highs on positive top-line data in exploratory trial of SAGE-547 in Postpartum Depression Print
By Josh Gee   
Tuesday, 09 June 2015 15:12

SAGE Therapeutics Inc. (NASDAQ:SAGE) has brought out the top-line data from exploratory clinical trial which shows that a big improvement in depression from a baseline level in four women with postpartum depression (PPD) in less than 24 hours through SAGE-547.

 

 During the treatment, all patients were able to get remission as gauged by Hamilton Rating Scale for Depression.

 

Patients had mean HAM-D score of 26.5 at baseline and got better to mean HAM-D score of 1.8 at the end of 60-hour treatment period.

 

The patients also witnessed improvement as gauged by Clinical Global Impression-Improvement scale. SAGE-547 was good in patients as it did not show any major bad events during the 30-day follow-up period.

 

Samantha Meltzer-Brody, M.D., Director of the Perinatal Psychiatry Program, University of North Carolina Center for Women's Mood Disorders and Principal Investigator of the trial, opined that severe severe postpartum depression is a major depressive disorder and the fact the SAGE-547 is showing results is encouraging.

 

She added that the firm was looking forward on continuing the study in the placebo-controlled trial.

 

PPD approximately affects 20% of women following childbirth.

Jeff Jonas, M.D., chief executive officer of SAGE, opined that the top-line results show an encouraging signal of activity in women having major PPD and he added that it proves that SAGE-547 mechanism of action has ability to impact broad range of disorders beyond epilepsy.

Jonas added that the firm plans to shift from initial open-label exploratory trial into placebo-controlled trial to prove activity signal.

He added that the firm has planned to improve a number of novel product candidates from extensive compound library which may suit treatment of the disorder.

Stephen Kanes, M.D., Ph.D., chief medical officer of SAGE, expressed gratitude to the patients for participating in the trial as well as the staff at the Perinatal Psychiatry Inpatient Unit at UNC Neurosciences Hospital.

Shares of the company are up 14% to $85.62 after hitting a new high of $89.04.

 




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!